243 related articles for article (PubMed ID: 32044284)
21. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
Clemente MG; Mandato C; Poeta M; Vajro P
World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
[TBL] [Abstract][Full Text] [Related]
22. The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD).
Thondam SK; Cuthbertson DJ; Wilding JPH
Peptides; 2020 Mar; 125():170208. PubMed ID: 31759125
[TBL] [Abstract][Full Text] [Related]
23. Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASH.
Boesch M; Lindhorst A; Feio-Azevedo R; Brescia P; Silvestri A; Lannoo M; Deleus E; Jaekers J; Topal H; Topal B; Ostyn T; Wallays M; Smets L; Van Melkebeke L; Härtlova A; Roskams T; Bedossa P; Verbeek J; Govaere O; Francque S; Sifrim A; Voet T; Rescigno M; Gericke M; Korf H; van der Merwe S
J Hepatol; 2024 Mar; 80(3):397-408. PubMed ID: 37977244
[TBL] [Abstract][Full Text] [Related]
24. Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome.
Lim S; Taskinen MR; Borén J
Obes Rev; 2019 Apr; 20(4):599-611. PubMed ID: 30589487
[TBL] [Abstract][Full Text] [Related]
25. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome.
Dietrich P; Hellerbrand C
Best Pract Res Clin Gastroenterol; 2014 Aug; 28(4):637-53. PubMed ID: 25194181
[TBL] [Abstract][Full Text] [Related]
26. Electrophilic nitro-oleic acid reverses obesity-induced hepatic steatosis.
Khoo NKH; Fazzari M; Chartoumpekis DV; Li L; Guimaraes DA; Arteel GE; Shiva S; Freeman BA
Redox Biol; 2019 Apr; 22():101132. PubMed ID: 30769284
[TBL] [Abstract][Full Text] [Related]
27. Hepatic Lipidomics and Molecular Imaging in a Murine Non-Alcoholic Fatty Liver Disease Model: Insights into Molecular Mechanisms.
Rodríguez-Calvo R; Samino S; Girona J; Martínez-Micaelo N; Ràfols P; García-Altares M; Guaita-Esteruelas S; Junza A; Heras M; Yanes O; Correig X; Masana L
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32899418
[TBL] [Abstract][Full Text] [Related]
28. Inflammation initiates a vicious cycle between obesity and nonalcoholic fatty liver disease.
Luo Y; Lin H
Immun Inflamm Dis; 2021 Mar; 9(1):59-73. PubMed ID: 33332766
[TBL] [Abstract][Full Text] [Related]
29. Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders.
Lim S; Oh TJ; Koh KK
Int J Cardiol; 2015 Dec; 201():408-14. PubMed ID: 26310987
[TBL] [Abstract][Full Text] [Related]
30. Iron and non-alcoholic fatty liver disease.
Britton LJ; Subramaniam VN; Crawford DH
World J Gastroenterol; 2016 Sep; 22(36):8112-22. PubMed ID: 27688653
[TBL] [Abstract][Full Text] [Related]
31. Genetic inactivation of the LIGHT (TNFSF14) cytokine in mice restores glucose homeostasis and diminishes hepatic steatosis.
Herrero-Cervera A; Vinué Á; Burks DJ; González-Navarro H
Diabetologia; 2019 Nov; 62(11):2143-2157. PubMed ID: 31388695
[TBL] [Abstract][Full Text] [Related]
32. Non-alcoholic fatty liver disease: A sign of systemic disease.
Reccia I; Kumar J; Akladios C; Virdis F; Pai M; Habib N; Spalding D
Metabolism; 2017 Jul; 72():94-108. PubMed ID: 28641788
[TBL] [Abstract][Full Text] [Related]
33. Adiponectin, a key adipokine in obesity related liver diseases.
Buechler C; Wanninger J; Neumeier M
World J Gastroenterol; 2011 Jun; 17(23):2801-11. PubMed ID: 21734787
[TBL] [Abstract][Full Text] [Related]
34. Macrophage Function in the Pathogenesis of Non-alcoholic Fatty Liver Disease: The Mac Attack.
Oates JR; McKell MC; Moreno-Fernandez ME; Damen MSMA; Deepe GS; Qualls JE; Divanovic S
Front Immunol; 2019; 10():2893. PubMed ID: 31921154
[TBL] [Abstract][Full Text] [Related]
35. Mesenteric adipose tissue B lymphocytes promote local and hepatic inflammation in non-alcoholic fatty liver disease mice.
Wu Z; Xu J; Tan J; Song Y; Liu L; Zhang F; Zhang Y; Li X; Chi Y; Liu Y
J Cell Mol Med; 2019 May; 23(5):3375-3385. PubMed ID: 30772951
[TBL] [Abstract][Full Text] [Related]
36. Human germline hedgehog pathway mutations predispose to fatty liver.
Guillen-Sacoto MJ; Martinez AF; Abe Y; Kruszka P; Weiss K; Everson JL; Bataller R; Kleiner DE; Ward JM; Sulik KK; Lipinski RJ; Solomon BD; Muenke M
J Hepatol; 2017 Oct; 67(4):809-817. PubMed ID: 28645738
[TBL] [Abstract][Full Text] [Related]
37. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions.
Gerges SH; Wahdan SA; Elsherbiny DA; El-Demerdash E
Life Sci; 2021 Apr; 271():119220. PubMed ID: 33592199
[TBL] [Abstract][Full Text] [Related]
38. Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice.
Chiang H; Lee JC; Huang HC; Huang H; Liu HK; Huang C
Br J Pharmacol; 2020 Jan; 177(2):239-253. PubMed ID: 31497874
[TBL] [Abstract][Full Text] [Related]
39. [METABOLIC FEATURES OF ADIPOSE TISSUE AND CLINICAL SIGNIFICANCE OF ADIPOKINS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (REVIEW)].
Pivtorak K; Yakovleva O; Pivtorak N; Fedzhaga I; Doroshkevich I
Georgian Med News; 2021; (316-317):135-141. PubMed ID: 34511460
[TBL] [Abstract][Full Text] [Related]
40. Nrg4 promotes fuel oxidation and a healthy adipokine profile to ameliorate diet-induced metabolic disorders.
Chen Z; Wang GX; Ma SL; Jung DY; Ha H; Altamimi T; Zhao XY; Guo L; Zhang P; Hu CR; Cheng JX; Lopaschuk GD; Kim JK; Lin JD
Mol Metab; 2017 Aug; 6(8):863-872. PubMed ID: 28752050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
